
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1879093/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Heart failure-related quality-of-life impairment after myocardial infarction. Clinical Research in Cardiology, 2023, 112, 39-48.	3.3	6
2	Subclinical Pulmonary Congestion and Abnormal Hemodynamics in HeartÂFailure With Preserved EjectionÂFraction. JACC: Cardiovascular Imaging, 2022, 15, 629-637.	5.3	10
3	Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity. European Journal of Heart Failure, 2022, 24, 353-361.	7.1	22
4	Pulmonary Vasculature Responsiveness to Phosphodiesterase-5A Inhibition in Heart Failure With Reduced Ejection Fraction: Possible Role of Plasma Potassium. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	2
5	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circulation: Heart Failure, 2022, 15, .	3.9	10
6	(Vericiguat - soluble guanylate cyclase stimulator, in therapy of heart failure). Cor Et Vasa, 2022, 64, 316-319.	0.1	0
7	Myocardial ketone body utilization in patients with heart failure: The impact of oral ketone ester. Metabolism: Clinical and Experimental, 2021, 115, 154452.	3.4	48
8	Acute Unloading Effects of Sildenafil Enhance Right Ventricular–Pulmonary Artery Coupling in Heart Failure. Journal of Cardiac Failure, 2021, 27, 224-232.	1.7	14
9	Heart failure after myocardial infarction: incidence and predictors. ESC Heart Failure, 2021, 8, 222-237.	3.1	243
10	Donor specific anti-HLA antibodies and cardiac allograft vasculopathy: A prospective study using highly automated 3-D optical coherence tomography analysis. Transplant Immunology, 2021, 65, 101340.	1.2	5
11	The effect of three major coâ€morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 1417-1426.	3.1	5
12	Ventricular–Arterial Interaction in Patients With Heart Failure and a Preserved Ejection Fraction. , 2021, , 71-85.		0
13	Renal Sympathetic Denervation Attenuates Congestive Heart Failure in Angiotensin II-Dependent Hypertension: Studies with Ren-2 Transgenic Hypertensive Rats with Aortocaval Fistula. Kidney and Blood Pressure Research, 2021, 46, 95-113.	2.0	8
14	Effects of renal sympathetic denervation on the course of congestive heart failure combined with chronic kidney disease: Insight from studies with fawn-hooded hypertensive rats with volume overload induced using aorto-caval fistula. Clinical and Experimental Hypertension, 2021, 43, 522-535.	1.3	9
15	Salutary Acute Effects of Exercise on Central Hemodynamics in Heart Failure With Preserved Ejection Fraction. Journal of Cardiac Failure, 2021, 27, 1313-1320.	1.7	5
16	Trends in the treatment and survival of heart failure patients: a nationwide populationâ€based study in the Czech Republic. ESC Heart Failure, 2021, 8, 3800-3808.	3.1	9
17	Right versus left ventricular remodeling in heart failure due to chronic volume overload. Scientific Reports, 2021, 11, 17136.	3.3	21
18	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Election Fraction (VICTORIA), Circulation, 2021, 144, 1489-1499.	1.6	21

#	Article	IF	CITATIONS
19	Kidney Response to Chemotherapy-Induced Heart Failure: mRNA Analysis in Normotensive and Ren-2 Transgenic Hypertensive Rats. International Journal of Molecular Sciences, 2021, 22, 8475.	4.1	0
20	Effects of Trandolapril on Structural, Contractile and Electrophysiological Remodeling in Experimental Volume Overload Heart Failure. Frontiers in Pharmacology, 2021, 12, 729568.	3.5	6
21	Very low lipoprotein(a) and increased mortality risk after myocardial infarction. European Journal of Internal Medicine, 2021, 91, 33-39.	2.2	8
22	(Expert consensus statement on the significance of iron deficiency and the possibilities of its) Tj ETQq0 0 0 rgBT	Overlock	۲ 10 Tf 50 622
23	(Practical aspects of establishing of heart failure clinics). Cor Et Vasa, 2021, 63, 619-625.	0.1	1
24	Expert consensus on the importance of iron deficiency and the possibility of its correction in patients with heart failure. Vnitrni Lekarstvi, 2021, 67, 495-497.	0.2	1
25	Heart rate and early progression of cardiac allograft vasculopathy: A prospective study using highly automated 3â€Ð optical coherence tomography analysis. Clinical Transplantation, 2020, 34, e13773.	1.6	4
26	Danon disease is an underdiagnosed cause of advanced heart failure in young female patients: a LAMP2 flow cytometric study. ESC Heart Failure, 2020, 7, 2534-2543.	3.1	8
27	Exercise dynamics of cardiac biomarkers and hemoconcentration in patients with chronic systolic heart failure. Journal of Cardiac Failure, 2020, 26, 1100-1105.	1.7	3
28	Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat. International Journal of Molecular Sciences, 2020, 21, 9337.	4.1	11
29	ACUTE EFFECTS OF PHOSPHODIESTERASE-5 INHIBITION ON RIGHT VENTRICULAR FUNCTION IN ADVANCED HFREF: THE INSIGHT FROM PRESSURE-VOLUME ANALYSIS. Journal of the American College of Cardiology, 2020, 75, 848.	2.8	Ο
30	Dysregulation of epicardial adipose tissue in cachexia due to heart failure: the role of natriuretic peptides and cardiolipin. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1614-1627.	7.3	24
31	Complete recovery of fulminant cytotoxic CD8 Tâ€cellâ€mediated myocarditis after ECMELLA unloading and immunosuppression. ESC Heart Failure, 2020, 7, 1976-1981.	3.1	6
32	Innate Lymphoid Cells Play a Pathogenic Role in Pericarditis. Cell Reports, 2020, 30, 2989-3003.e6.	6.4	24
33	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412.	7.1	193
34	Noninvasive evaluation of pulmonary artery pressure during exercise: the importance of right atrial hypertension. European Respiratory Journal, 2020, 55, 1901617.	6.7	33
35	Desminopathy: Novel Desmin Variants, a New Cardiac Phenotype, and Further Evidence for Secondary Mitochondrial Dysfunction. Journal of Clinical Medicine, 2020, 9, 937.	2.4	24
36	Renal sympathetic denervation attenuates congestive heart failure in angiotensin IIâ€dependent hypertension: studies with Renâ€2 transgenic hypertensive rats with aortoâ€caval fistula. FASEB Journal, 2020, 34, 1-1.	0.5	1

VOJTECH MELENOVSKY

#	Article	IF	CITATIONS
37	434-P: Possible Mechanisms of Cardioprotective Effects of Metformin in Patients with Type 2 Diabetes and Chronic Heart Failure. Diabetes, 2020, 69, 434-P.	0.6	0
38	2140-PUB: Effect of Metformin on Incretin Secretion in Patients with Diabetes and Chronic Heart Failure. Diabetes, 2020, 69, 2140-PUB.	0.6	0
39	(Expert consensus statement of the Czech Heart Failure Association of the Czech Society of) Tj ETQq1 1 0.7843	14 rgBT /C	)veglock 10 Th
40	Abstract 14613: Preclinical Animal Model of Doxorubicin-induced Left Ventricular Dysfunction: Echocardiography and Pressure-volume Analysis. Circulation, 2020, 142, .	1.6	0
41	Independent effect of atrial fibrillation on natriuretic peptide release. Clinical Research in Cardiology, 2019, 108, 142-149.	3.3	25
42	The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. European Heart Journal, 2019, 40, 3721-3730.	2.2	155
43	The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction. European Heart Journal, 2019, 40, 3707-3717.	2.2	47
44	Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. Kidney and Blood Pressure Research, 2019, 44, 792-809.	2.0	14
45	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	2.2	944
46	Clinical and Humoral Determinants of Congestion in Heart Failure: Potential Role of Adiponectin. Kidney and Blood Pressure Research, 2019, 44, 1271-1284.	2.0	5
47	Myocardial iron homeostasis and hepcidin expression in a rat model of heart failure at different levels of dietary iron intake. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 703-713.	2.4	20
48	Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. Frontiers in Pharmacology, 2019, 10, 18.	3.5	9
49	Mitochondrial Function, Skeletal Muscle Metabolism, and Iron Deficiency in Heart Failure. Circulation, 2019, 139, 2399-2402.	1.6	15
50	Coronary Artery Disease Is Associated with an Increased Amount of T Lymphocytes in Human Epicardial Adipose Tissue. Mediators of Inflammation, 2019, 2019, 1-9.	3.0	14
51	Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. European Heart Journal, 2019, 40, 689-697.	2.2	190
52	The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease. Canadian Journal of Cardiology, 2019, 35, 462-470.	1.7	22
53	MitraClip in patients with functional mitral regurgitation and advanced heart failure - Single centre experience. Cor Et Vasa, 2019, 61, 8-14.	0.1	1
54	406-P: Effect of Metformin on Dicarbonyl Stress in Patients with Type 2 Diabetes and Chronic Heart Failure. Diabetes, 2019, 68, .	0.6	0

#	Article	IF	CITATIONS
55	2-OR: Metabolic Inflexibility in Patients with Type 2 Diabetes and Heart Failure. Diabetes, 2019, 68, 2-OR.	0.6	0
56	Early detection of cardiac allograft vasculopathy using highly automated 3-dimensional optical coherence tomography analysis. Journal of Heart and Lung Transplantation, 2018, 37, 992-1000.	0.6	26
57	Heterogeneous aetiology and clinical presentation of cardiac involvement in hypereosinophilic syndrome: A case series. Cor Et Vasa, 2018, 60, e321-e326.	0.1	1
58	Early progression of cardiac allograft vasculopathy assessed by quantitative coronary angiography: A single centre prospective study. Cor Et Vasa, 2018, 60, e59-e65.	0.1	1
59	Transition from angiotensin-converting enzyme inhibitor/angiotensin-II-receptor-blocker to sacubitril/valsartan in chronic heart failure patients: Initial experiences in clinical practice. Cor Et Vasa, 2018, 60, e209-e214.	0.1	1
60	Impact of Atrial Fibrillation on Natriuretic Peptides. JACC: Clinical Electrophysiology, 2018, 4, 153-154.	3.2	3
61	Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome. Kidney and Blood Pressure Research, 2018, 43, 1437-1450.	2.0	25
62	Myocardial Injury and Cardiac Reserve Limitation in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure, 2018, 24, S21-S22.	1.7	0
63	Temporal Changes in Right Ventricular Structure and Function in Patients with Heart Failure and Preserved Ejection Fraction. Journal of Cardiac Failure, 2018, 24, S5.	1.7	Ο
64	Quantitative 3D Analysis of Coronary Wall Morphology in Heart Transplant Patients: OCT-Assessed Cardiac Allograft Vasculopathy Progression. Medical Image Analysis, 2018, 50, 95-105.	11.6	19
65	Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure. Circulation: Heart Failure, 2018, 11, e004800.	3.9	44
66	Proteinâ€losing enteropathy in an adult with nonâ€ischaemic cardiomyopathy: complete reversal by heart transplantation. ESC Heart Failure, 2018, 5, 842-845.	3.1	6
67	Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction. European Heart Journal, 2018, 39, 2810-2821.	2.2	180
68	Hemodynamic Correlates and DiagnosticÂRole of Cardiopulmonary Exercise Testing in Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2018, 6, 665-675.	4.1	132
69	Isovolumic loading of the failing heart by intraventricular placement of a spring expander attenuates cardiac atrophy after heterotopic heart transplantation. Bioscience Reports, 2018, 38, .	2.4	6
70	Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. European Heart Journal, 2018, 39, 2825-2835.	2.2	165
71	Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and PreservedÂEjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 29-40.	2.8	106
72	Gut Incretin Release as a Mediator of Metabolic Effects of Metformin in Type 2 Diabetic Patients with Chronic Heart Failure. Diabetes, 2018, 67, 465-P.	0.6	0

#	Article	IF	CITATIONS
73	Aortic Waveform Analysis to Individualize Treatment in Heart Failure. Circulation: Heart Failure, 2017, 10, .	3.9	23
74	Resting and Exercise-Induced Left Atrial Hypertension in Patients WithÂAtrial Fibrillation. JACC: Clinical Electrophysiology, 2017, 3, 461-469.	3.2	21
75	Percutaneous Pericardial Resection. Circulation: Heart Failure, 2017, 10, e003612.	3.9	72
76	Value of Assessment of Exercise Hemodynamics in Patients With Atrial Fibrillation. Journal of Cardiac Failure, 2017, 23, 656.	1.7	0
77	A Complex Heart Team's Approach to a Patient With Giant Cell Myocarditis. Canadian Journal of Cardiology, 2017, 33, 1335.e5-1335.e7.	1.7	1
78	ARTERIAL RESERVE LIMITATIONS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION AND THE BENEFICIAL EFFECTS OF SODIUM NITRITE. Journal of the American College of Cardiology, 2017, 69, 880.	2.8	0
79	Long-term cardiovascular changes following creation of arteriovenous fistula in patients with end stage renal disease. European Heart Journal, 2017, 38, 1913-1923.	2.2	93
80	Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation, 2017, 136, 6-19.	1.6	689
81	THE ROLE OF DIASTOLIC STRESS TESTING IN THE EVALUATION FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION: AN INVASIVE-ECHOCARDIOGRAPHIC STUDY. Journal of the American College of Cardiology, 2017, 69, 879.	2.8	1
82	Reply to â€~Cardiac remodeling after reduction of high-flow arteriovenous fistulas in end-stage renal disease: methodological issues'. Hypertension Research, 2017, 40, 411-411.	2.7	0
83	Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction. Circulation, 2017, 135, 825-838.	1.6	416
84	Increased Heart Rate After Heart Transplant Is Not Associated with Early Progression of Cardiac Allograft Vasculopathy (CAV) - A Prospective Study Using Highly Automatic Coronary Optical Coherence Tomography Segmentation Software in 3D. Journal of Heart and Lung Transplantation, 2017, 36, S297-S298.	0.6	1
85	Glucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	13
86	Relationships between Novel Biomarkers and Hemodynamics during Exercise in Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure, 2017, 23, S33-S34.	1.7	0
87	Arterial Stiffening With Exercise in PatientsÂWith Heart Failure and PreservedÂEjection Fraction. Journal of the American College of Cardiology, 2017, 70, 136-148.	2.8	195
88	Heart rate response to exercise in heart failure patients: The prognostic role of metabolic–chronotropic relation and heart rate recovery. International Journal of Cardiology, 2017, 228, 588-593.	1.7	7
89	Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. European Journal of Heart Failure, 2017, 19, 522-530.	7.1	180
90	Analysis of immune cell populations in atrial myocardium of patients with atrial fibrillation or sinus rhythm. PLoS ONE, 2017, 12, e0172691.	2.5	52

#	Article	IF	CITATIONS
91	Clinical correlates of B-type natriuretic peptide monitoring in outpatients with left ventricular assist device. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2017, 161, 68-74.	0.6	7
92	B-type natriuretic peptide: powerful predictor of end-stage chronic heart failure in individuals with systolic dysfunction of the systemic right ventricle. Croatian Medical Journal, 2016, 57, 343-350.	0.7	4
93	Changes in Myocardial Composition and Conduction Properties in Rat Heart Failure Model Induced by Chronic Volume Overload. Frontiers in Physiology, 2016, 7, 367.	2.8	23
94	56-05: Outcome of Catheter Ablation of Atrial Fibrillation in Patients with Latent Heart Failure and Preserved Left Ventricular Ejection Fraction. Europace, 2016, 18, i33-i33.	1.7	1
95	Cardiac remodeling after reduction of high-flow arteriovenous fistulas in end-stage renal disease. Hypertension Research, 2016, 39, 654-659.	2.7	17
96	Biphasic response in number of stem cells and endothelial progenitor cells after left ventricular assist device implantation: A 6 month follow-up. International Journal of Cardiology, 2016, 218, 98-103.	1.7	11
97	Reply. Journal of the American College of Cardiology, 2016, 67, 1383-1384.	2.8	0
98	Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone. Canadian Journal of Cardiology, 2016, 32, 1574.e1-1574.e3.	1.7	17
99	Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Circulation Research, 2016, 119, 880-886.	4.5	133
100	Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance. Transplant International, 2016, 29, 63-72.	1.6	22
101	High-Output Heart Failure. Journal of the American College of Cardiology, 2016, 68, 473-482.	2.8	199
102	Early Detection of PAH in Patients With Systemic Connective Tissue Disease. Chest, 2016, 150, 1181A.	0.8	0
103	Geographic variation in the access to heart transplantation in the Czech Republic. Cor Et Vasa, 2016, 58, e396-e402.	0.1	1
104	Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. European Heart Journal, 2016, 37, 3293-3302.	2.2	259
105	Comparison of Cystatin C and NGAL in Early Diagnosis of Acute Kidney Injury After Heart Transplantation. Annals of Transplantation, 2016, 21, 329-245.	0.9	23
106	Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in <scp>R</scp> enâ€2 transgenic hypertensive rats with aortoâ€caval fistula. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 795-807.	1.9	41
107	Lung congestion in chronic heart failure: haemodynamic, clinical, and prognostic implications. European Journal of Heart Failure, 2015, 17, 1161-1171.	7.1	109
108	Bioptic Study of Left and Right Atrial Interstitium in Cardiac Patients with and without Atrial Fibrillation: Interatrial but Not Rhythm-Based Differences. PLoS ONE, 2015, 10, e0129124.	2.5	27

#	Article	IF	CITATIONS
109	Response to Letter Regarding "Differential Hemodynamic Effects of Exercise and Volume Expansion in People With and Without Heart Failure― Circulation: Heart Failure, 2015, 8, 411-411.	3.9	0
110	Etiology, Characteristics and Clinical Outcomes in High Output Heart Failure: A 15 Year Experience. Journal of Cardiac Failure, 2015, 21, S69.	1.7	1
111	Left Atrial Remodeling and Function in Advanced Heart Failure With Preserved or Reduced Ejection Fraction. Circulation: Heart Failure, 2015, 8, 295-303.	3.9	345
112	Impact of chronic changes in arterial compliance and resistance on left ventricular ageing in humans. European Journal of Heart Failure, 2015, 17, 27-34.	7.1	27
113	Differential Hemodynamic Effects of Exercise and Volume Expansion in People With and Without Heart Failure. Circulation: Heart Failure, 2015, 8, 41-48.	3.9	167
114	The Effect of Diabetes Mellitus on Cardiac Mitochondria in Patients With End-Stage Heart Failure. Journal of Heart and Lung Transplantation, 2015, 34, S90.	0.6	0
115	Cardiac Allograft Vasculopathy Assessed By Quantitative Coronary Angiography: A Single Center Prospective Study. Journal of Heart and Lung Transplantation, 2015, 34, S297-S298.	0.6	Ο
116	Enhanced Pulmonary Vasodilator Reserve and Abnormal Right Ventricular. Circulation: Heart Failure, 2015, 8, 542-550.	3.9	83
117	Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic SystolicÂHeartÂFailure. JACC: Heart Failure, 2015, 3, 829-839.	4.1	59
118	Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2015, 66, 1672-1682.	2.8	188
119	Fully Automated Ultrasensitive Digital Immunoassay for Cardiac Troponin I Based on Single Molecule Array Technology. Clinical Chemistry, 2015, 61, 1283-1291.	3.2	21
120	Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascular Pharmacology, 2015, 73, 45-56.	2.1	14
121	Abstract 13596: Magnetic Resonance - Derived Pre-contrast T1 Relaxation Time is the Accurate Marker of Diffuse Myocardial Fibrosis in Severe Aortic Valve Disease: A Comparison With Left Ventricular Myocardial Biopsy. Circulation, 2015, 132, .	1.6	0
122	Abstract 16305: Cardiac and Circulatory Adaptation to Volume Overload: The Impact of Reduction of High-flow Arterio-venous Fistula. Circulation, 2015, 132, .	1.6	1
123	A Randomized Pilot Study of Aortic Waveform Guided Therapy in Chronic Heart Failure. Journal of the American Heart Association, 2014, 3, .	3.7	1
124	A Randomized Pilot Study of Aortic Waveform Guided Therapy in Chronic Heart Failure. Journal of the American Heart Association, 2014, 3, e000745.	3.7	41
125	Implications of Coronary Artery Disease in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 63, 2817-2827.	2.8	233
126	Right heart dysfunction in heart failure with preserved ejection fraction. European Heart Journal, 2014, 35, 3452-3462.	2.2	491

VOJTECH MELENOVSKY

#	Article	IF	CITATIONS
127	Differential Hemodynamic Effects of Exercise and Acute Volume Expansion in HFpEF. Journal of Cardiac Failure, 2014, 20, S13-S14.	1.7	Ο
128	Impact of General and Central Adiposity onÂVentricular-Arterial Aging inÂWomen and Men. JACC: Heart Failure, 2014, 2, 489-499.	4.1	70
129	Relationships Between Right Ventricular Function, Body Composition, and Prognosis inÂAdvanced Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1660-1670.	2.8	131
130	The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: A case–control study. International Journal of Cardiology, 2013, 168, 60-65.	1.7	34
131	Resting Heart Rate and Heart Rate Reserve inÂAdvancedÂHeart Failure Have Distinct Pathophysiologic Correlates and Prognostic Impact. JACC: Heart Failure, 2013, 1, 259-266.	4.1	46
132	Cardiac Adaptation to Volume Overload. , 2013, , 167-199.		6
133	Assessment of optimal right ventricular pacing site using invasive measurement of left ventricular systolic and diastolic function. Europace, 2013, 15, 1482-1490.	1.7	9
134	Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2013, 15, 776-785.	7.1	275
135	Longitudinal Changes in Left Ventricular Stiffness. Circulation: Heart Failure, 2013, 6, 944-952.	3.9	140
136	Availability of energetic substrates and exercise performance in heart failure with or without diabetes. European Journal of Heart Failure, 2012, 14, 754-763.	7.1	12
137	The Course of Heart Failure Development and Mortality in Rats with Volume Overload due to Aorto-Caval Fistula. Kidney and Blood Pressure Research, 2012, 35, 167-173.	2.0	40
138	Use of the Frank-Starling mechanism during exercise is linked to exercise-induced changes in arterial load. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H349-H358.	3.2	18
139	The Effects of Phosphodiesterase 5 Inhibition on Hemodynamics, Functional Status, and Survival in Advanced Heart Failure and Pulmonary Hypertension: A Case-Control Study. Chest, 2012, 142, 79A.	0.8	Ο
140	359 Long-Term Sildenafil Therapy in Advanced HF Patients with Severe PH Improves Hemodynamics and Prevents Weight Loss. Journal of Heart and Lung Transplantation, 2012, 31, S127-S128.	0.6	0
141	Clinical predictors of outcome in survivors of out-of-hospital cardiac arrest treated with hypothermia. Cor Et Vasa, 2012, 54, e68-e75.	0.1	9
142	Lipolytic Effects of B-Type Natriuretic Peptide1–32 in Adipose Tissue of Heart Failure Patients Compared With Healthy Controls. Journal of the American College of Cardiology, 2011, 58, 1119-1125.	2.8	60
143	Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats. Clinical Science, 2011, 121, 29-41.	4.3	50
144	Metabolic characterization of volume overload heart failure due to aorto-caval fistula in rats. Molecular and Cellular Biochemistry, 2011, 354, 83-96.	3.1	50

#	Article	IF	CITATIONS
145	Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2. Proteome Science, 2011, 9, 69.	1.7	39
146	Myocardial Morphological Characteristics and Proarrhythmic Substrate in the Rat Model of Heart Failure Due to Chronic Volume Overload. Anatomical Record, 2011, 294, 102-111.	1.4	29
147	Intermittent Cardiogenic Shock in a Man With Mechanical Prosthesis of the Aortic Valve. Circulation, 2011, 124, e1-3.	1.6	4
148	Should Prostacycline Be the First Line Treatment of PAA in Patients With PAH. Chest, 2011, 140, 727A.	0.8	0
149	Transpulmonary B-Type Natriuretic Peptide Uptake and Cyclic Guanosine Monophosphate Release in Heart Failure and Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, 595-600.	2.8	65
150	RELATION BETWEEN ACUTE AND LONG-TERM EFFECT OF SILDENAFIL IN PATIENTS WITH ADVANCED HEART FAILURE AND SEVERE PULMONARY HYPERTENSION. Chest, 2009, 136, 103S.	0.8	0
151	Aortic dissection in a young man with Loeys–Dietz syndrome. Journal of Thoracic and Cardiovascular Surgery, 2008, 135, 1174-1175.e1.	0.8	11
152	Interleukin-8 and atrial fibrillation. Europace, 2008, 10, 784-785.	1.7	8
153	The sex-specific impact of systolic hypertension and systolic blood pressure on arterial-ventricular coupling at rest and during exercise. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H145-H153.	3.2	47
154	High Basal Metabolic Rate Is a Risk Factor for Mortality: The Baltimore Longitudinal Study of Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 698-706.	3.6	120
155	Ventricular-Arterial Interaction in Patients with Heart Failure and a Preserved Ejection Fraction. , 2008, , 403-412.		0
156	Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. Journal of Hypertension, 2007, 25, 577-583.	0.5	176
157	Estimation of central pressure augmentation using automated radial artery tonometry. Journal of Hypertension, 2007, 25, 1403-1409.	0.5	44
158	Cardiovascular Features of Heart Failure With Preserved Ejection Fraction Versus Nonfailing Hypertensive Left Ventricular Hypertrophy in the Urban Baltimore Community. Journal of the American College of Cardiology, 2007, 49, 198-207.	2.8	425
159	Impact of Arterial Load and Loading Sequence on Left Ventricular Tissue Velocities in Humans. Journal of the American College of Cardiology, 2007, 50, 1570-1577.	2.8	280
160	Synergistic Effects of Systolic Hypertension and Female Sex on the Arterialâ€Ventricular Coupling Ratio. FASEB Journal, 2007, 21, A1260.	0.5	0
161	Hemodynamics and Autonomic Control of Heart Rate Turbulence. Journal of Cardiovascular Electrophysiology, 2006, 17, 286-291.	1.7	40
162	Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation, 2006, 114, 2138-2147.	1.6	586

VOJTECH MELENOVSKY

#	Article	IF	CITATIONS
163	Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. European Heart Journal, 2005, 26, 705-711.	2.2	54
164	Impact of ventricular response irregularity in patients with atrial fibrillation and heart failure. European Heart Journal, 2005, 26, 1689-1690.	2.2	2
165	Impact of ventricular response irregularity in patients with atrial fibrillation and heart failure: reply. European Heart Journal, 2005, 26, 1690-1690.	2.2	0
166	Pulse wave analysis during supine rest may identify subjects with recurrent vasovagal syncope. Clinical Science, 2005, 109, 165-170.	4.3	12
167	Relation between actual heart rate and autonomic effects of beta blockade in healthy men. American Journal of Cardiology, 2005, 95, 999-1002.	1.6	22
168	Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans. Circulation, 2005, 112, 2642-2649.	1.6	161
169	Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 932-943.	2.4	1,451
170	Short-Term Effects of Right-Left Heart Sequential Cardiac Resynchronization in Patients With Heart Failure, Chronic Atrial Fibrillation, and Atrioventricular Nodal Block. Circulation, 2004, 110, 3404-3410.	1.6	120
171	Repeatability of noninvasive surrogates of endothelial function. American Journal of Cardiology, 2004, 94, 693-696.	1.6	30
172	Hypolipidemic drugs, blood pressure, heart rate, heart rate variability and sympathetic activity. International Congress Series, 2004, 1262, 458-461.	0.2	2
173	Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. American Heart Journal, 2003, 146, 110A-115A.	2.7	22
174	Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. American Journal of Cardiology, 2003, 92, 337-341.	1.6	31
175	Lipid lowering and the assessment of endothelial function. Cardiovascular Research, 2002, 54, 191-192.	3.8	0
176	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. American Heart Journal, 2002, 144, G1-G8.	2.7	11
177	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. American Heart Journal, 2002, 144, E6.	2.7	56
178	Von Willebrand factor and assessment of endothelial function. Cardiovascular Research, 2002, 54, 193-194.	3.8	5
179	Nitroglycerin Induced Syncope Occurs in Subjects with Delayed Phase Shift of Baroreflex Action. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 828-832.	1.2	7
180	Mechanisms involved in heart rate turbulence. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 262-266.	1.0	40

#	Article	IF	CITATIONS
181	Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial — FAT). Cardiovascular Research, 2001, 52, 290-298.	3.8	131
182	Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition, 2001, 17, 721-723.	2.4	57
183	Cross-Spectral Analysis of Heart Rate and Blood Pressure Modulations. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 1425-1430.	1.2	8
184	Stability of the noninvasive baroreflex sensitivity assessment using crossâ€spectral analysis of heart rate and arterial blood pressure variabilities. Clinical Cardiology, 2000, 23, 201-204.	1.8	7
185	Penetration of Antibiotics into the Pancreas in Rats: An Effect of Acute Necrotizing Pancreatitis. Scandinavian Journal of Gastroenterology, 1999, 34, 92-97.	1.5	15